Corcept Therapeutics Incorporated (BIT:1CORT)

Market Cap	3.62B -39.8%
Revenue (ttm)	631.70M +17.9%
Net Income	89.20M -25.2%
EPS	0.74 -30.7%
Shares Out	n/a
PE Ratio	40.60
Forward PE	47.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	755
Open	n/a
Previous Close	35.05
Day's Range	n/a
52-Week Range	28.78 - 77.84
Beta	n/a
RSI	39.45
Earnings Date	Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CORT

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD